Last reviewed 2026-04-22 · How we verify

Post-transplant Grazoprevir and Elbasvir

Grazoprevir and elbasvir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease and NS5A protein, respectively, preventing viral replication.

Grazoprevir and elbasvir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease and NS5A protein, respectively, preventing viral replication. Used for Chronic hepatitis C virus infection in post-transplant patients (liver transplant recipients).

At a glance

Mechanism of action

Grazoprevir targets the HCV NS3/4A serine protease, which is essential for processing viral polyproteins. Elbasvir inhibits the NS5A protein, which is critical for viral RNA replication and assembly. Together, this combination directly blocks multiple steps of the HCV life cycle, achieving high cure rates in HCV-infected patients, including those in the post-transplant setting where standard treatments may be contraindicated or less effective.

Approved indications

• Chronic hepatitis C virus infection in post-transplant patients (liver transplant recipients)

Common side effects

• Headache
• Fatigue
• Nausea
• Diarrhea

Key clinical trials

• HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant (PHASE4)
• HepATocellular Cancer Hcv Therapy Study (PHASE3)
• Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients (EARLY_PHASE1)
• Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.